Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238624 | 0.92 | F2 (0.70) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7808994 | 0.89 | F2 (0.74) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8186956 | 0.82 | F2 (0.57) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL31742245 | 0.82 | F2 (0.70) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7406265 | 0.82 | F2 (0.55) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7025245 | 0.81 | F2 (0.55) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7159962 | 0.81 | F2 (0.70) | F2PRSS1 | |
| Acetic Acid SCHEMBL31742242 | 0.81 | F2 (0.67) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5474694 | 0.80 | F2 (0.64) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7220542 | 0.79 | F2 (0.47) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030110-B2 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6476016-B2 | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | F2 12/4885PRSS1 15/4885PRSS2 21/4885 |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | F2 12/4885PRSS1 15/4885PRSS2 21/4885 |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, TFPI, F12 | F2 9/4885PRSS1 15/4885PRSS2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.